Amgevita Launch In Finland Is No Counterbalance For Remsima Loss, Orion Anticipates
Executive Summary
Intensified competition and declining prices, coupled with a failure to scoop winner-takes-all tenders in certain Nordic markets, took a huge bite out of Orion’s biosimilars sales in 2018. Launching the first Humira biosimilar in Finland will not plug the gap, the company has stated.